Tredje AP-fonden’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $46.6M | Buy |
1,658,914
+308,914
| +23% | +$8.22M | 0.25% | 80 |
|
|
2025
Q4 | $33.6M | Buy |
+1,350,000
| New | +$34M | 0.25% | 84 |
|
|
2025
Q1 | – | Sell |
-274,098
| Closed | -$7.27M | – | 470 |
|
|
2024
Q4 | $7.27M | Sell |
274,098
-14,427
| -5% | -$391K | 0.07% | 175 |
|
|
2024
Q3 | $8.35M | Hold |
288,525
| – | – | 0.08% | 158 |
|
|
2024
Q2 | $8.07M | Hold |
288,525
| – | – | 0.08% | 148 |
|
|
2024
Q1 | $8.01M | Sell |
288,525
-499,247
| -63% | -$13.9M | 0.08% | 151 |
|
|
2023
Q4 | $22.7M | Buy |
787,772
+55,410
| +8% | +$1.68M | 0.28% | 80 |
|
|
2023
Q3 | $24.3M | Buy |
732,362
+4,175
| +0.6% | +$148K | 0.36% | 67 |
|
|
2023
Q2 | $26.7M | Buy |
728,187
+11,035
| +2% | +$430K | 0.38% | 69 |
|
|
2023
Q1 | $29.3M | Sell |
717,152
-242,493
| -25% | -$10.5M | 0.45% | 60 |
|
|
2022
Q4 | $49.2M | Buy |
959,645
+87,844
| +10% | +$4.21M | 0.84% | 23 |
|
|
2022
Q3 | $38.1M | Buy |
871,801
+349,006
| +67% | +$17M | 0.79% | 25 |
|
|
2022
Q2 | $27.4M | Sell |
522,795
-2,000
| -0.4% | -$102K | 0.69% | 29 |
|
|
2022
Q1 | $27.2M | Buy |
524,795
+2,500
| +0.5% | +$130K | 0.55% | 38 |
|
|
2021
Q4 | $30.8M | Buy |
522,295
+18,926
| +4% | +$938K | 0.6% | 33 |
|
|
2021
Q3 | $21.6M | Hold |
503,369
| – | – | 0.45% | 51 |
|
|
2021
Q2 | $19.7M | Buy |
503,369
+7,500
| +2% | +$292K | 0.4% | 54 |
|
|
2021
Q1 | $18M | Hold |
495,869
| – | – | 0.43% | 61 |
|
|
2020
Q4 | $18.3M | Sell |
495,869
-26,777
| -5% | -$982K | 0.47% | 63 |
|
|
2020
Q3 | $18.2M | Hold |
522,646
| – | – | 0.59% | 44 |
|
|
2020
Q2 | $16.2M | Sell |
522,646
-105,400
| -17% | -$3.58M | 0.67% | 35 |
|
|
2020
Q1 | $19.4M | Buy |
628,046
+23,436
| +4% | +$799K | 1.01% | 22 |
|
|
2019
Q4 | $22.5M | Sell |
604,610
-98,084
| -14% | -$3.49M | 1.14% | 12 |
|
|
2019
Q3 | $24M | Buy |
702,694
+43,914
| +7% | +$1.6M | 1.15% | 14 |
|
|
2019
Q2 | $27.1M | Sell |
658,780
-29,516
| -4% | -$1.17M | 1.29% | 12 |
|
|
2019
Q1 | $27.7M | Buy |
688,296
+26,761
| +4% | +$1.07M | 1.44% | 9 |
|
|
2018
Q4 | $27.4M | Sell |
661,535
-141,047
| -18% | -$5.86M | 1.67% | 8 |
|
|
2018
Q3 | $33.6M | Sell |
802,582
-426,125
| -35% | -$16.4M | 1.62% | 6 |
|
|
2018
Q2 | $42.3M | Buy |
1,228,707
+267,917
| +28% | +$9.16M | 1.47% | 6 |
|
|
2018
Q1 | $32.4M | Buy |
960,790
+95,894
| +11% | +$3.3M | 1.15% | 7 |
|
|
2017
Q4 | $29.7M | Buy |
864,896
+91,545
| +12% | +$3.12M | 1.01% | 9 |
|
|
2017
Q3 | $26.2M | Buy |
773,351
+8,950
| +1% | +$288K | 0.93% | 9 |
|
|
2017
Q2 | $24.4M | Sell |
764,401
-51,075
| -6% | -$1.61M | 0.91% | 12 |
|
|
2017
Q1 | $26.5M | Buy |
815,476
+50,202
| +7% | +$1.58M | 1.04% | 9 |
|
|
2016
Q4 | $23.6M | Buy |
765,274
+11,730
| +2% | +$358K | 1% | 11 |
|
|
2016
Q3 | $24.2M | Sell |
753,544
-82,395
| -10% | -$2.76M | 1.09% | 9 |
|
|
2016
Q2 | $27.9M | Sell |
835,939
-71,853
| -8% | -$2.29M | 1.25% | 8 |
|
|
2016
Q1 | $28.8M | Sell |
907,792
-117,307
| -11% | -$3.35M | 1.32% | 9 |
|
|
2015
Q4 | $31.4M | Buy |
1,025,099
+227,275
| +28% | +$7.15M | 2.01% | 4 |
|
|
2015
Q3 | $23.8M | Buy |
797,824
+792,198
| +14,081% | +$25.4M | 2.32% | 4 |
|
|
2015
Q2 | $179K | Buy |
+5,626
| New | +$183K | 0.01% | 295 |
|
Other funds holding PFE
VCM
VPM
Tredje AP-fonden's PFE Position: Q1 2026 in Review
Tredje AP-fonden increased its Pfizer (PFE) stake by 23% in Q1 2026, buying an estimated $8.22M and bringing the position to 1,658,914 shares worth $46.6M. The position accounts for 0.25% of the portfolio, ranked #80.
Tredje AP-fonden first reported a position in PFE in Q2 2015 and has held it in 41 quarters since. The position peaked at $49.2M in Q4 2022. 2,939 funds tracked by Wall St. Rank hold PFE as of Q1 2026.
- Tredje AP-fonden held 1,658,914 shares of Pfizer worth $46.6M as of Q1 2026.
- Tredje AP-fonden bought 308,914 Pfizer shares in Q1 2026, an estimated $8.22M.
- Pfizer made up 0.25% of Tredje AP-fonden's portfolio in Q1 2026, its #80 holding.
- Tredje AP-fonden first reported a position in Pfizer in Q2 2015 and has held it in 41 quarters since.
- Tredje AP-fonden's Pfizer position peaked at $49.2M in Q4 2022.
- 2,939 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.
Based on Tredje AP-fonden's 13F filing for Q1 2026, filed 12 May 2026.